Nature Biotechnology: FDA go-ahead to test cellular rejuvenation therapy in humans Peer-reviewed
Partial Epigenetic Reprogramming Reaches Human Trials: What Longevity Clinics Can — and Cannot — Claim
Life Biosciences' ER-100 trial is a milestone for partial epigenetic reprogramming, but it is not an approved longevity-clinic treatment.